Pherin Signs Licensing Agreement with VistaGen Therapeutics

Sept 13, 2018 - Pherin Pharmaceuticals is pleased to report that a worldwide licensing agreement has been reached with VistaGen® Therapeutics to develop and commercialize PH94B nasal spray for as-needed treatment of Social Anxiety Disorder (SAD). Read the September 13, 2018 VistaGen press release.

Dr. Michael Liebowitz Appointed to VistaGen Clinical and Regulatory Advisory Board

Oct 15, 2018 - VistaGen® Therapeutics Appoints Dr. Michael Liebowitz to CNS Clinical and Regulatory Advisory Board in Preparation for Pivotal Phase 3 Development of PH94B as the First Rapid-Acting, On- Demand Treatment of Social Anxiety Disorder. Read the October 15, 2018 VistaGen press release.

Product Pipeline

Pherin Pharmaceuticals, Inc. is a leader in the development of first-in-class compounds administered as a nasal spray in ultra-low (nanogram or low microgram) doses, without the need of systemic exposure and with a demonstrated excellent safety profile.

We have a diverse product portfolio that increases the probability for commercial success. We believe that the therapeutic advantages of our product candidates will result in pherines becoming an important new class of approved pharmaceuticals.

Currently we have five development programs focused on the acute, intermittant, and long-term treatment of neuro-psychiatric and neuroendocrine conditions.

 

PH94B

Pherin Pharmaceuticals lead program PH94B nasal spray, a Phase 3 ready product, is being developed for the acute treatment of Social Anxiety Disorder under USFDA regulatory guidance.

Unique Nanodose Pharmaceuticals

Pherin Pharmaceuticals, Inc. is a privately held clinical stage drug development company that discovered and is developing a new family of first-in-class proprietary compounds called pherines for the acute, intermittent and long-term treatment of neuropsychiatric and neuroendocrine conditions.

Noteworthy

Rapid onset of efficacy and as needed (PRN) administration for treatment of Social Anxiety Disorder: a multicenter randomized controlled with placebo clinical trial with PH94B nasal spray. Clinically Significant Improvement of Social Anxiety Disorder Symptoms During a Public Speaking Challenge.